IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

[1]  F. Gaillard.  TERT promoter mutations , 2017, Radiopaedia.org.

[2]  Charmaine D. Wilson,et al.  Mitotic Index is an Independent Predictor of Recurrence‐Free Survival in Meningioma , 2015, Brain pathology.

[3]  R. Verhaak,et al.  Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas , 2014, Genome Biology.

[4]  Pieter Wesseling,et al.  International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.

[5]  David T. W. Jones,et al.  Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma , 2014, Acta Neuropathologica.

[6]  T. Jiang,et al.  ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples , 2014, Oncotarget.

[7]  Caterina Giannini,et al.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Darell D. Bigner,et al.  Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas , 2014, Oncotarget.

[9]  R. McLendon,et al.  The genetic landscape of anaplastic astrocytoma , 2013, Oncotarget.

[10]  T. Holland-Letz,et al.  ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis , 2013, Acta Neuropathologica.

[11]  M. Campone,et al.  Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience , 2013, Journal of Neuro-Oncology.

[12]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[13]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. J. van den Bent,et al.  Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Lei Han,et al.  Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. , 2012, Neuro-oncology.

[17]  Timothy A. Chan,et al.  Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma , 2012, Oncotarget.

[18]  Minako Sumi,et al.  IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. , 2012, International journal of oncology.

[19]  B. Klink,et al.  The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas , 2012, Journal of Neuro-Oncology.

[20]  A. von Deimling,et al.  Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event , 2012, PloS one.

[21]  R. McLendon,et al.  Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.

[22]  A. Unterberg,et al.  No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas , 2012, Journal of Neuro-Oncology.

[23]  Christian Hartmann,et al.  IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom , 2012, Seizure.

[24]  J. Huse,et al.  IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma , 2012, Clinical Cancer Research.

[25]  G. Schackert,et al.  IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas , 2012, Journal of Neuro-Oncology.

[26]  K. Ichimura.  Molecular pathogenesis of IDH mutations in gliomas , 2012, Brain Tumor Pathology.

[27]  A. Mukasa,et al.  Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients , 2012, Cancer science.

[28]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[29]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Torp,et al.  Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study , 2011, Diagnostic pathology.

[31]  G. Reifenberger,et al.  Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? , 2011, Clinical Cancer Research.

[32]  Henry Brem,et al.  Central nervous system cancers. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  G. Reifenberger,et al.  Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas , 2010, Acta Neuropathologica.

[34]  O. Chinot,et al.  Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis , 2010, Acta Neuropathologica.

[35]  R. Guillevin,et al.  IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas , 2010, Neurology.

[36]  G. Reifenberger,et al.  Molecular diagnostics of gliomas: state of the art , 2010, Acta Neuropathologica.

[37]  K. Aldape,et al.  High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors , 2010, Journal of Neuro-Oncology.

[38]  Martin J. Bent,et al.  Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective , 2010, Acta Neuropathologica.

[39]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[40]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[41]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[42]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[44]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[45]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  T. Tominaga,et al.  Analysis of IDH1 and IDH2 mutations in Japanese glioma patients , 2009, Cancer science.

[47]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[48]  Mitchel S. Berger,et al.  Operative techniques for gliomas and the value of extent of resection , 2009, Neurotherapeutics.

[49]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[50]  Susan M. Chang,et al.  Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. , 2008, Journal of neurosurgery.

[51]  R. Jenkins,et al.  Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. , 2008, Cancer journal.

[52]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[53]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[55]  Caterina Giannini,et al.  Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome , 2007, Journal of neuropathology and experimental neurology.

[56]  H Duffau,et al.  Temozolomide for low-grade gliomas , 2007, Neurology.

[57]  Arie Perry,et al.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.

[58]  N. Chen,et al.  Apoptosis and Proliferation Markers in Diffusely Infiltrating Astrocytomas: Profiling of 17 Molecules , 2006, Journal of neuropathology and experimental neurology.

[59]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Denis Lacombe,et al.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Caterina Giannini,et al.  Assessment and Prognostic Significance of Mitotic Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-grade Infiltrating Astrocytomas , 2006, The American journal of surgical pathology.

[62]  Caterina Giannini,et al.  The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors , 2005, Cancer.

[63]  Henry Brem,et al.  Central nervous system cancers. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[64]  Desmond Curran,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  K. Aldape,et al.  Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. , 2001, The American journal of pathology.

[66]  B. Fisher,et al.  Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. , 1999, International journal of radiation oncology, biology, physics.

[67]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[68]  C. Allis,et al.  Chromatin Condensation Is Not Associated with Apoptosis* , 1998, The Journal of Biological Chemistry.

[69]  C. Allis,et al.  Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation , 1997, Chromosoma.

[70]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[72]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[73]  J. Schramm,et al.  TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. , 2015, Neuro-oncology.

[74]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.

[75]  信澤 純人.  Molecular classification of low-grade diffuse gliomas , 2012 .

[76]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[77]  J. Uhm.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .

[78]  Webster K. Cavenee,et al.  WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .